Article
Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
Neuro-oncology - 1 Aug 2022
Meißner Anna-Katharina, Gutsche Robin, Galldiks Norbert, Kocher Martin, Jünger Stephanie T, Eich Marie-Lisa, Montesinos-Rongen Manuel, Brunn Anna, Deckert Martina, Wendl Christina, Dietmaier Wolfgang, Goldbrunner Roland, Ruge Maximilian I, Mauch Cornelia, Schmidt Nils-Ole, Proescholdt Martin, Grau Stefan, Lohmann Philipp
Abstract excerpt
BACKGROUND: The BRAF V600E mutation is present in approximately 50% of patients with melanoma brain metastases and an important prerequisite for response to targeted therapies, particularly BRAF inhibitors. As heterogeneity in terms of BRAF mutation status may occur in melanoma patients, a wild-type extracranial primary tumor does not necessarily rule out a targetable mutation in brain metastases using BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.